Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
Autore:
Wirth, M; Tyrrell, C; Wallace, M; Delaere, KP; Sanchez-Chapado, M; Ramon, J; Hetherington, J; Pina, F; Heynes, CF; Borchers, TM; Morris, T; Stone, A;
Indirizzi:
Tech Univ Dresden, Sch Med, Dept Urol, D-01307 Dresden, Germany Tech Univ Dresden Dresden Germany D-01307 Urol, D-01307 Dresden, Germany Derriford Hosp, Plymouth Oncol Ctr, Plymouth PL6 8DH, Devon, England Derriford Hosp Plymouth Devon England PL6 8DH uth PL6 8DH, Devon, England Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England Queen Elizabeth Hosp Birmingham W Midlands England B15 2TH lands, England Ziekenhuis de Wever Gregorius, Heerlen, Netherlands Ziekenhuis de Wever Gregorius Heerlen Netherlands Heerlen, Netherlands Hosp Principe Asturias, Madrid, Spain Hosp Principe Asturias Madrid Spain sp Principe Asturias, Madrid, Spain Chaim Sheba Med Ctr, Dept Urol, IL-52621 Tel Hashomer, Israel Chaim Sheba Med Ctr Tel Hashomer Israel IL-52621 21 Tel Hashomer, Israel Princes Royal Hosp, Kingston Upon Hull, N Humberside, England Princes Royal Hosp Kingston Upon Hull N Humberside England side, England Hosp Sao Joao, Serv Urol, Oporto, Portugal Hosp Sao Joao Oporto Portugal osp Sao Joao, Serv Urol, Oporto, Portugal Univ Stellenbosch, Fac Med, ZA-7505 Tygerberg, South Africa Univ Stellenbosch Tygerberg South Africa ZA-7505 Tygerberg, South Africa Tygerberg Hosp, Tygerberg, South Africa Tygerberg Hosp Tygerberg South Africa erg Hosp, Tygerberg, South Africa Turret House, Cape Town, South Africa Turret House Cape Town South Africa rret House, Cape Town, South Africa AstraZeneca, Macclesfield, Cheshire, England AstraZeneca Macclesfield Cheshire England acclesfield, Cheshire, England
Titolo Testata:
UROLOGY
fascicolo: 2, volume: 58, anno: 2001,
pagine: 146 - 150
SICI:
0090-4295(200108)58:2<146:B(1MAI>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOMASTIA; TAMOXIFEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Wirth, M Tech Univ Dresden, Sch Med, Dept Urol, Fetscherstasse 74, D-01307Dresden,Germany Tech Univ Dresden Fetscherstasse 74 Dresden Germany D-01307 many
Citazione:
M. Wirth et al., "Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression", UROLOGY, 58(2), 2001, pp. 146-150

Abstract

Objectives. To investigate the efficacy and tolerability of bicalutamide (Casodex) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with localized or locally advanced (T1b-T4, any nodal status, MO) prostate cancer. Methods. This was a multicenter, prospective, randomized, double-blind, placebo-controlled trial in Europe, South Africa, Australia, and Mexico and is part of the Casodex Early Prostate Cancer program. Results. A total of 3603 men were randomized to receive bicalutamide (n = 1798) or placebo (n = 1805) The patient demographics were well balanced between the two groups. Prior therapy of curative intent had been given to 64%of the patients (prostatectomy [44%], radiotherapy [18%], and prostatectomy and radiotherapy [2%]) and 36% had been monitored with watchful waiting. After a median follow-up of 2.6 years and a median exposure to the study drug of 2.2 years, a significant 43% reduction in the risk of objective progression was observed for the bicalutamide group compared with the placebo group (hazard ratio 0.57, 95% confidence interval 0.48 to 0.69, P <<0.0001). The time to prostate-specific antigen doubling was significantly delayed for the bicalutamide group compared with the placebo group (hazard ratio 0.37, 95% confidence interval 0.32 to 0.43, P <<0.001). The survival data were immature, with 7.2% overall mortality. The most frequently reported adverseevents with bicalutamide were gynecomastia alone (17.4%), breast pain alone (17.6%), and gynecomastia with breast pain (47.5%). Conclusions. Bicalutamide 150 mg daily as immediate therapy, alone or as adjuvant to treatment of curative intent, significantly reduced the risk of disease progression in patients with localized or locally advanced prostatecancer. Longer follow-up is underway to assess any benefit in overall survival. UROLOGY 58: 146-151, 2001 (C) 2001, Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 03:42:56